ENTITY
Eris Lifesciences

Eris Lifesciences (ERIS IN)

65
Analysis
Health Care • India
Eris Lifesciences Limited manufactures, markets, and sells generic drugs. The Company focuses on cardiology, diabetology, endocrinology, gastroenterology, ENT, orthopedics, pediatrics, and gynecology segments. Eris Lifesciences distributes pharmaceutical drugs throughout India. v
more
•19 Aug 2024 23:06

Indian Pharmaceutical Market: On A Healthy Growth Path; Momentum to Continue in Rest of the Year

​Indian pharmaceutical market grew 8.7% in Q1FY25. Most of the top players reported double-digit revenue growth in domestic market. Nifty Pharma...

Logo
425 Views
Share
•24 Jul 2024 11:30

Akums Drugs and Pharmaceuticals Pre-IPO - Profitable but Needs to Scale up More

Akums Drugs and Pharmaceuticals (0200361D IN) is looking to raise up to US$239m in its upcoming India IPO. In this note, we talk about the...

Logo
Ethan Aw
415 Views
Share
•09 Jul 2024 14:14

Emcure Pharma Pre-IPO Trading - Strong Subscription, Will Pop

Emcure Pharmaceuticals raised around US$240m in its India IPO. Subscription rates were strong for institutional and HNI tranche.

Logo
357 Views
Share
•03 Jul 2024 10:10

Emcure Pharmaceuticals Pre-IPO - Refiling Updates and Valuations

Emcure Pharmaceuticals is looking to raise around US$240m in its upcoming India IPO. In this note, we talk about valuations.

Logo
2.6k Views
Share
bullish•Indegene
•10 May 2024 11:28

Indegene IPO Trading - High Anchor Quality + Strong Demand, Expect a Pop on Debut

Indegene Limited (1864095D IN) raised around US$220m in its India IPO, via selling a mix of primary and secondary shares. In this note, we will...

Logo
613 Views
Share
x